Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

Université Laval

$123,000.00

Comprehensive screening for novel epigenetic targets in advanced ovarian cancer by functional epigenomics

EF 2009-10

Résumé
Ovarian cancer (OC) accounts for 4% of all cancers in women and is the leading cause of death from gynaecologic malignancies. The molecular basis of OC initiation and progression is still poorly understood. To establish novel therapeutic and diagnostic strategies against this deadly disease, it is essential to understand its molecular pathology. One of the key pathogenic elements underlying human cancer is disruption of normal gene regulation. Recently, the importance of epigenetic perturbation of gene regulation in cancer linked with aberrant DNA methylation has begun to be more fully appreciated. Our project aims to identify novel genes with aberrant DNA methylation that might be implicated in OC etiology. The proposed research represents a systematic approach for the identification of novel OC epigenetic targets, starting with genome-wide discovery, quantitative and robust methylation analysis and proceeding with epigenetic marker validation across many OC samples. We also propose to develop and implement post-processing software needed for the quantitative methylation analyses, as well as novel primer-design software, which could considerably improve the targeted amplification of specific bisulfite-treated DNA promoter sites. A cost-effective, high-throughput DNA methylation analysis tool would help tremendously to understand the relationship between the status of the tens of thousands of potential methylation sites and disease and might provide novel biomarkers for improved diagnosis, prognosis and treatment of OC. The innovative technologies and methodological approaches proposed could be ultimately applied for epigenetic target discovery and validation in other cancer types.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
351583-2008
Name nom
Bachvarov, Dimcho
Department département
Médecine
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
123000
Program id
CHRPJ
Program nane en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
2
Nb partie
3
Application title
Comprehensive screening for novel epigenetic targets in advanced ovarian cancer by functional epigenomics
Keyword
NA
Application summary
Ovarian cancer (OC) accounts for 4% of all cancers in women and is the leading cause of death from gynaecologic malignancies. The molecular basis of OC initiation and progression is still poorly understood. To establish novel therapeutic and diagnostic strategies against this deadly disease, it is essential to understand its molecular pathology. One of the key pathogenic elements underlying human cancer is disruption of normal gene regulation. Recently, the importance of epigenetic perturbation of gene regulation in cancer linked with aberrant DNA methylation has begun to be more fully appreciated. Our project aims to identify novel genes with aberrant DNA methylation that might be implicated in OC etiology. The proposed research represents a systematic approach for the identification of novel OC epigenetic targets, starting with genome-wide discovery, quantitative and robust methylation analysis and proceeding with epigenetic marker validation across many OC samples. We also propose to develop and implement post-processing software needed for the quantitative methylation analyses, as well as novel primer-design software, which could considerably improve the targeted amplification of specific bisulfite-treated DNA promoter sites. A cost-effective, high-throughput DNA methylation analysis tool would help tremendously to understand the relationship between the status of the tens of thousands of potential methylation sites and disease and might provide novel biomarkers for improved diagnosis, prognosis and treatment of OC. The innovative technologies and methodological approaches proposed could be ultimately applied for epigenetic target discovery and validation in other cancer types.